Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.61 |
| ▸ | ACACA | Q13085 | 11/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458482 | 0.93 | ACACB (0.72) | ACACBACACA | |
| SCHEMBL2349857 | 0.93 | ACACB (0.72) | ACACBACACA | |
| SCHEMBL6113829 | 0.93 | ACACB (0.72) | ACACBACACA | |
| SCHEMBL25469386 | 0.84 | ACACB (0.41) | ACACBACACAMAOAMAOB | |
| SCHEMBL6113639 | 0.80 | ACACB (0.61) | ACACBACACA | |
| SCHEMBL2352652 | 0.80 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL2347653 | 0.80 | ACACB (0.61) | ACACBACACA | |
| SCHEMBL6113656 | 0.80 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL13103247 | 0.80 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL13103222 | 0.79 | ACACB (0.58) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | ACACB 85/4885ACACA 90/4885MAOA 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.